A multinational study of health state preference values associated with chronic myelogenous leukemia

Value in Health

Volumn 13, Issue 1, 2010, Pages 103-111

  Szabo, Shelagh M ^a   Levy, Adrian R ^a,b   Davis, Catherine ^c   Holyoake, Tessa L ^d   Cortes, Jorge ^e  

^a ICON PLC   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Health state utility; Preferences; Societal; Utility assessment

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; CANADA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES;

EID: 72949124188     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00573.x     Document Type: Article

References (67)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
2. Andritsos L, Khoury H. Chronic lymphocytic leukemia. Curr Treat Options Oncol 2002 3 : 225 231.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999 340 : 1330 1340.
4. Williams JP, Handler HL. Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia. Am J Manag Care 2000 6 : S975 85.
5. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 348 : 994 1004.
6. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002 99 : 3530 3539. (Pubitemid 34534519)
7. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002 100 : 1965 1971.
8. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 354 : 2531 2541. (Pubitemid 43882349)
9. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007 109 : 2303 2309. (Pubitemid 46425867)
10. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007 109 : 4143 4150. (Pubitemid 46743375)
11. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002 99 : 1928 1937. (Pubitemid 34525471)
12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 355 : 2408 2417.
13. Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986 314 : 1065 1069.
14. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995 122 : 254 261.
15. Talpaz M, Mavligit G, Keating M, et al. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 1983 99 : 789 792.
16. O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999 93 : 4149 4153.
17. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002 94 : 2024 2032.
18. Kantarjian HM, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999 17 : 284 292.
19. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997 337 : 223 229.
20. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002 99 : 1527 1535.
21. Homewood J, Watson M, Richards SM, et al. Treatment of CML using IFN-alpha: impact on quality of life. Hematol J 2003 4 : 253 262.
22. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003 21 : 2138 2146.
23. Kluin-Nelemans HC, Buck G, le Cessie S, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004 103 : 4408 4415.
24. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006 108 : 1478 1484.
25. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006 108 : 1835 1840.
26. Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007 109 : 1556 1560.
27. Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005 23 : 515 526.
28. Dalziel K, Round A, Stein K, et al. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004 8 : iii, 1 120.
29. Redaelli A, Stephens JM, Laskin BL, et al. The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Expert Rev Anticancer Ther 2003 3 : 311 329.
30. Cohen L, de Moor C, Amato RJ. The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial. Cancer 2001 91 : 1949 1955.
31. Bertero C, Eriksson BE, Ek AC. Explaining different profiles in quality of life experiences in acute and chronic leukemia. Cancer Nurs 1997 20 : 100 104.
32. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 1996 94 : 324 332.
33. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004 101 : 2574 2583.
34. Gordois A, Scuffham P, Warren E, Ward S. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer 2003 89 : 634 640.
35. Warren E, Ward S, Gordois A, Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 2004 26 : 1924 1933.
36. McDonough CM, Tosteson AN. Measuring preferences for cost-utility analysis: how choice of method may influence decision-making. Pharmacoeconomics 2007 25 : 93 106.
37. Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006 95 : 683 690.
38. Levy AR, Krowdley K, Iloeje UH, et al. The impact of chronic hepatitis B disease progression on quality of life: a multinational study of health state preferences from infected and uninfected persons. Value Health 2008 11 : 527 538.
39. Levy AR, Christensen T, Johnson J. Utility values symptomatic non-severe hypoglycemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008 6 : 73 80.
40. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 33 : 337 343.
41. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998 12 : 31 80. (Pubitemid 28119350)
42. Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985 66 : 1326 1335.
43. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 346 : 645 652.
44. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006 81 : 973 988.
45. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988 25 : 49 61.
46. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002 100 : 2292 2302.
47. Griesshammer M, Arnold R, Bangerter M, et al. Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol 1998 61 : 7 13.
48. Griesshammer M, Heinze B, Hellmann A, et al. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol 1996 73 : 225 230.
49. Bennet KJ, Torrance GW. Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). Philadelphia : Lippincott-Raven Press, 1996.
50. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986 5 : 1 30.
51. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976 10 : 128 136.
52. Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 2008 62 : 374 380.
53. Hoffmann JP. Generalized Linear Models: An Applied Approach. Boston, MA : Pearson Education Inc, 2004.
54. Covinsky KE, Fuller JD, Yaffe K, et al. Communication and decision-making in seriously ill patients: findings of the SUPPORT project. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc 2000 48 : S187 93.
55. Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 2004 49 : 453 458.
56. Schackman BR, Teixeira PA, Weitzman G, et al. Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making 2008 28 : 233 242.
57. Stein JD, Brown MM, Brown GC, et al. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol 2003 87 : 8 12.
58. Elstein AS, Chapman GB, Chmiel JS, et al. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect 2004 7 : 115 125.
59. Elstein AS, Chapman GB, Knight SJ. Patients' values and clinical substituted judgments: the case of localized prostate cancer. Health Psychol 2005 24 : S85 92.
60. Solomon MJ, Pager CK, Keshava A, et al. What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis Colon Rectum 2003 46 : 1351 1357.
61. Harrison JD, Solomon MJ, Young JM, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg 2008 143 : 389 394.
62. Janz NK, Wren PA, Copeland LA, et al. Patient-physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol 2004 22 : 3091 3098.
63. Gold M, Siefel JE, Russell LB, Weinstein MC. Cost Effectivenss in Health and Medicine. Oxford : Oxford University Press, 1996.
64. National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London : National Institute for Clinical Excellence, 2004.
65. Torrance GW. Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006 24 : 1069 1078.
66. Stalmeier PF, Lamers LM, Busschbach JJ, Krabbe PF. On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences. Med Care 2007 45 : 835 841.
67. Australian Bureau of Statistics. Australian Standard Classification of Cultural and Ethnic Groups. http://www.abs.gov.au/AUSSTATS/abs@nsf/DetailsPage/ 124902000-01?OpenDocument 2006 Accessed February 25, 2009 ].